Among 44,486 evaluable participants, irrespective of prior SARS-CoV-2 infection, 81 COVID-19 cases were observed among vaccine and 873 among placebo recipients.
of those
COVID-19: 0 BNT162b2 vs 2 for placebo
COVID-19: pneumonia 1 for BNT162b2 vs 0 for placebo
Cardiac arrest: 4 for BNT162b2 vs 1 for placebo
but despite these, it seems there is no statistically significant effect on fatality either way
As for Adverse Events, after reading this:
Adverse event analyses during the blinded period are provided for 43,847 ≥16-year-olds . Reactogenicity events among participants not in the reactogenicity subset are reported as adverse events, resulting in imbalances in adverse events (30% vs 14%), related adverse events (24% vs 6%), and severe adverse events (1.2% vs 0.7%) between BNT162b2 and placebo groups. Decreased appetite, lethargy, asthenia, malaise, night sweats, and hyperhidrosis were new adverse events attributable to BNT162b2 not previously identified in earlier reports.
Here's the official Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine vs Placebo
On p.12 of the Supplementary material is the table of fatalities.
Total 15 for BNT162b2 vs 14 for placebo
of those
COVID-19: 0 BNT162b2 vs 2 for placebo
COVID-19: pneumonia 1 for BNT162b2 vs 0 for placebo
Cardiac arrest: 4 for BNT162b2 vs 1 for placebo
but despite these, it seems there is no statistically significant effect on fatality either way
As for Adverse Events, after reading this:
I wouldn't even want the placebo !
Sometimes their placebo is all the adjuvants. They are at least half the problem.
Blimey.
#The placebo is worse than the disease.